The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the introduction of CASGEVY, the first CRISPR/Cas9 gene-editing therapy in the UAE.

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

For teenagers with sickle cell disease, these years can be even more challenging due to the impact of chronic pain, fatigue, hospital visits, and lifestyle restrictions. SCD is a genetic blood ...

Data on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta thalassaemia and sickle cell disease suggest they can reduce symptoms. The closely-watched trial ...

For sickle cell disease, the FDA has approved a CRISPR/Cas9 therapy that silences the Bcl11a gene to increase fetal hemoglobin production. In osteogenesis imperfecta, studies have demonstrated the ...

CRISPR uses gene-editing technology to modify or correct DNA sequences, providing an opportunity to treat genetic disorders. Casgevy, a sickle cell treatment developed by Vertex and CRISPR ...

After birth, the BCL11A gene instructs the body to produce adult ... With the NHS approval of CASGEVY – the UK’s first CRISPR-based therapy for sickle cell disease – it is estimated that around 50 ...

The membrane distortion of cells can enhance the delivery of CRISPR/Cas systems into cells with low cell toxicity. In physical methods, DNA/mRNA/protein without any carrier is transferred into cells, ...

Living with sickle cell disease means navigating the unpredictability of pain crises – those sudden, excruciating episodes that often lead to emergency room visits. For patients and their ...